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B-type natriuretic peptide versus amino terminal
pro-B type natriuretic peptide: selecting the
optimal heart failure marker in patients with
impaired kidney function
Lena Jafri1, Waqar Kashif2, Javed Tai2, Imran Siddiqui1, Iqbal Azam3, Hira Shahzad4 and Farooq Ghani1*
Abstract
Background: The effect of impaired kidney function on B-type natriuretic peptide (BNP) and N-terminal proBNP
(NT-proBNP) is vague. This study was performed to examine the effect of kidney dysfunction on the afore-mentioned
markers and determine appropriate cutoffs for systolic heart failure (SHF).
Methods: In this cross sectional study adults with estimated glomerular filtration rate (eGFR) <60 ml/min for
≥3 months were identified in consulting clinics from June 2009 to March 2010. SHF was defined as documented by
a cardiologist with ejection fraction of < 40% and assessed by New York Heart Association classification (NYHA).
Plasma was assayed for creatinine (Cr), BNP and NT-proBNP.
Results: A total of 190 subjects were enrolled in the study, 95 with and 95 without SHF. The mean age of patients
was 58 (±15) years, 67.4% being males. Mean BNP levels showed a 2.5 fold and 1.5 fold increase from chronic kidney
disease (CKD) stage 3 to stage 5 in patients with and without SHF respectively. NT-proBNP levels in non-heart failure
group were 3 fold higher in CKD stage 5 compared to stage 3. Mean NT-proBNP levels were 4 fold higher in CKD
stage 5 compared to stage 3 in patients with SHF. Optimal BNP and NT-proBNP cutoffs of SHF diagnosis for the
entire CKD group were 300 pg/ml and 4502 pg/ml respectively.
Conclusion: BNP and NT-proBNP were elevated in kidney dysfunction even in the absence of SHF; however the
magnitude of increase in NT-proBNP was greater than that of BNP. BNP and NT-proBNP can be useful in diagnosing
SHF, nonetheless, by using higher cutoffs stratified according to kidney dysfunction. NT-proBNP appears to predict
heart failure better than BNP.
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Background
Literature from the United States, Australia and China
report the prevalence of chronic kidney disease (CKD)
as ranging from 11–13.1% [1-4]. Community based stud-
ies in Pakistan reveal a high burden of CKD ranging
from 15 to 20% in subjects older than 40 years of age
[5]. The exact prevalence of CKD in Pakistan is still un-
known due to lack of documentation and funds, but it is
expected to be high, with respect to the observation of
the epidemic of diabetes and hypertension in this part of
the world [6-8]. The prevalence of heart failure increases
as glomerular filtration rate (GFR) declines and as many
as 35% of patients reaching end stage renal disease
already have clinical evidence of heart failure [9]. To
prevent the occurrence of heart failure a reliable marker
for observing cardiac overload in such patients is
needed. The B-type natriuretic peptide (BNP) and
N- terminal pro-hormone B-type natriuretic peptide
(NT-proBNP) are established heart failure markers but
concomitant presence of CKD changes their interpret-
ation in significant manner [10-13].
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The source of BNP and NT-proBNP are mainly left
ventricular myocytes. Distention of cardiac ventricle is
considered the main stimulus for release of proBNP1-108.
This pro-hormone is released into the circulation and is
proteolytically cleaved into the biologically active BNP1-32
and the inactive NT-proBNP1-76. The understanding of
the cleavage of proBNP in circulation is most likely by the
pro-protein convertases corin and furin [14,15]. The pro-
cessing of proBNP is indeed complex, with significant re-
lease of unprocessed proBNP, particularly in heart failure.
Several recent studies have demonstrated that there are
only small amounts of intact BNP in blood, and the major
circulating forms of BNP are degradation products. These
degradation products and intact proBNP are detected by
BNP assays to a varying extent [16]. The synthesis and re-
lease of BNP is controlled at the level of gene expression
which is predominantly controlled by ventricular hyper-
trophy, inflammation or stretch [17]. The clearance mech-
anism of BNP is through the endocytosis followed by
lysosomal degradation, and through the degradation by
the nonspecific membrane-bound enzyme neutral endo-
peptidase but NT-proBNP is mainly cleared via the kid-
neys [18-20]. Both are released in a 1:1 ratio but levels of
NT-proBNP are higher than that of BNP because of half-
life of 15–20 minutes whereas the half-life of NT-proBNP
has been estimated to be longer (1–2 hours) [21,22].
We presume that with declining kidney function. NT-
proBNP would be affected more as compared to BNP. The
ideal natriuretic peptide to diagnose heart failure in CKD
remains undecided. This study was conducted to evaluate
the effects of compromised kidney function on natriuretic
peptides (BNP or NT-proBNP) and to determine optimal
cutoffs predictable of systolic heart failure (SHF).
Methods
Study population and procedure
A cross-sectional study was conducted in the Section of
Chemical Pathology, Department of Pathology and Micro-
biology in collaboration with the nephrology and cardiac
units of Aga Khan University, Karachi Pakistan. It was
conducted over a period of 10 months from June 2009 to
March 2010. The Aga Khan University’s Ethical Review
Committee approved all investigational procedures in-
volved in the study (reference number: 1054-Path-ERC-08).
Recruitment of consecutive adult ambulatory subjects with
impaired kidney function was carried out via non-
probability quota sampling from the clinics. After taking in-
formed consent a proforma was filled including patient
demographics, clinical history, smoking history, history of
alcohol intake and drug history. The patient’s body weight
and height were recorded in order to determine the body
mass index (BMI).
Impaired kidney function was taken as estimated
glomerular filtration rate (eGFR) of ≤ 60 ml/min. The
Cockcroft Gault equation was used to estimate the GFR
of the study subjects from plasma creatinine (Cr), age
and body weight of the subjects [23]. The subjects strati-
fication was carried out into CKD stage 3 (eGFR 30–
60 ml/minute), stage 4 (eGFR 15–29 ml/minute), and
stage 5 (eGFR <15 ml/minute) [24]. Patients were classi-
fied as having SHF as per the interview data and physical
examination using New York Heart Association (NYHA)
and then reconfirmed from past echocardiography re-
port (ejection fraction <40%) or SHF documented on the
file by a cardiologist [25]. Patients on dialysis therapy
and obese patients with body mass index >30 kg/m2
were not included in this study. Both endogenous and
exogenous hormones have shown to induce elevated
levels of BNP/NT-proBNP in circulation therefore preg-
nant females, those on hormonal therapy or taking con-
traceptives were also not included in this study group
[26,27]. Six milliliter of blood sample was taken from
every participating patient into vacutainers containing
ethylene diamine tetra acetic acid (EDTA) for analysis.
Plasma was obtained after centrifugation of samples for
analyzing BNP, NT-proBNP and creatinine.
Biochemical measurements
Plasma samples were collected after informed consent and
centrifuged at 3000 g for 10 minutes, aliquoted, frozen and
maintained at −80°C. All samples were run in batches for
plasma BNP, NT-pro BNP and Cr. The BNP levels were
measured by automated electrochemiluminescence im-
munoassay (ECLIA) on Axym analyzer (Abbott diagnostic).
The NT-proBNP levels were measured by automated
ECLIA on Elecsys analyzer (Roche diagnostic). Plasma Cr
levels were assayed with the rate-Jaffe reaction (with a cali-
brator traceable to the isotope dilution mass spectrometry
reference method) on Synchron analyzer (Beckman
Coulter). To ensure quality, normal and abnormal con-
trols were run with every batch of BNP, NT-proBNP
and Cr analysis.
Statistical analysis
Data analysis was performed using SPSS version 19.
After checking for normality using the Kolomogorov-
Smirnove test, BNP and NT-proBNP values were log
transformed. Mean and ± standard deviation (SD) or me-
dian with 25th to 95th percentile for continuous variables
were computed. Dichotomous variables were expressed
in percentages. The differences between groups were tested
using t-test, one way analysis of variance (ANOVA) or Chi
square test, as applicable. Post-hoc comparisons of log
BNP/NT-proBNP in different groups were carried out
using Bonferroni method. Variables used in univariate ana-
lysis with p-value of < 0.2 were then entered in a multiple
regression model using ENTER method. Results were
reported as standardized ß-coefficient. Receiver operating
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characteristic (ROC) curves were constructed and areas
under the curve (AUC) calculated for BNP and NT-
proBNP to detect SHF. Compromising on sensitivity in
order to improve the specificity the uppermost corner on
the left side of the ROC curve was not used for calculating
cutoffs. A p-value of < 0.05 was treated as significant in all
above statistical analysis.
Results
Study population
Table 1 depicts the characteristics, medical history and bio-
chemical results of one hundred and ninety study subjects
enrolled in this study. The EF of all the study subjects was
available. The mean age of the study population was 58 ±
15 years and the majority was males (67.4%). The median
duration of impaired kidney function in subjects with
impaired kidney function with and without SHF was
18 months (Interquartile Range = 3 – 160 months) and
24 months (Interquartile Range = 6 – 190 months) respect-
ively (p-value > 0.05). Statistically non-significant difference
existed between mean log BNP/NT-proBNP amongst males
and females in those with and without SHF (p-value >0.05).
Multivariate predictors of natriuretic peptides
The following predictor variables were used in univariate
analysis taking log BNP/log NT-proBNP as the dependent
Table 1 Clinical characteristics and biochemical data of patients with impaired kidney function stratified into two
groups based on cardiac function
Characteristics of total subjects p value
Mean (±SD), n (%)
Overall Without SHF With SHF
n = 190 n = 95 n = 95
Age (years) 58 ± 15 53 ± 15 63 ± 14 0.00
Male gender (%) 128 (67.4) 59 (62.1) 69 (72.6) 0.12
BMI (kg/m2) 23 ± 3.1 24.1 ± 3.2 21.9 ± 2.5 0.00
Hypertension (%) 141 (74.6) 71 (74.7) 70 (73.7) 0.77
Anemia (%) 129 (67.9) 64 (67.4) 65 (68.4) 0.87
Diabetes (%) 108 (56.8) 49 (51.6) 59 (62.1) 0.14
Dyslipidemia (%) 69 (36.3) 33 (34.7) 36 (37.9) 0.65
Ischemic heart disease (%) 39 (20.5) 0 39 (41.1) 0.00
Smoking history (%) 6 (3.2) 1 (1.1) 5 (5.3) 0.09
Cerebrovascular accident (%) 4 (2.1) 1 (1.1) 3 (3.2) 0.31
Malignancy (%) 1 (0.5) 0 1 (1.1) 0.31
Alcohol intake (%) 1 (0.5) 1 (1.1) 0 0.31
ACE inhibitors 91 (47.9) 51 (53.7) 40 (42.1) 0.11
Statins 69 (36.3) 33 (34.7) 36 (37.9) 0.65
Calcium channel blockers 49 (25.8) 32 (33.7) 17 (17.9) 0.01
Diuretics 41 (21.6) 19 (20) 22 (23.2) 0.59
Digoxin 22 (11.6) 0 22 (23.2) 0.00
ARB 20 (10.5) 8 (8.4) 12 (12.6) 0.34
Beta blocker 13 (6.8) 12 (12.6) 1 (1.1) 0.00
Stage 3 CKD (%) 77 (40.5) 41 (43.2) 36 (37.9) 0.75
Stage 4 CKD (%) 77 (40.5) 37 (38.9) 40 (42.1) 0.75
Stage 5 CKD (%) 36 (18.9) 17 (17.9) 19 (20) 0.49
Ejection fraction (%) 42.9 ± 6.8 59.3 ± 3.5 26.6 ±10.2 0.00
eGFR (ml/min) 27.7 ± 14 29.1 ± 15.1 26.2 ± 12.9 0.15
Cr (mg/dl) 3.2 ± 2.2 3.3 ± 2.4 3.0 ± 1.8 0.34
Log BNP (pg/ml) 2.2 ± 0.5 2.0 ± 0.4 2.4 ± 0.6 0.00
Log NT-proBNP (pg/ml) 3.4 ± 0.6 2.9 ± 0.6 3.9 ± 0.6* 0.00
Abbreviations: SHF systolic heart failure, SD standard deviation, BMI body mass index, ACE angiotensin converting enzyme, ARB angiotensin receptor blocker, CKD
chronic kidney disease, eGFR estimated glomerular filtration rate, Cr creatinine, BNP b type natriuretic peptide, NT-proBNP Amino terminal B-type natriuretic peptide.
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variables: age, gender, BMI, eGFR, ejection fraction, dia-
betes, hypertension, ischemic heart disease, cerebrovascu-
lar accident, dyslipidemia, anemia, smoking history,
calcium channel blockers, beta-blockers, statins, digoxin,
angiotensin converting enzyme inhibitor, angiotensin re-
ceptor blocker, diuretics and duration of kidney disease.
Table 2 shows the final multivariate regression model for
both BNP and NT-proBNP based on total number of sub-
jects. Significant predictors of log NT-proBNP were found
to be age, BMI, SHF, NYHA stage, and eGFR. Concentra-
tion of NT-proBNP increased progressively with declining
kidney function estimated as eGFR. The log BNP and log
NT-proBNP showed inverse correlation with EF (r = −0.3
and −0.6 respectively). Both BNP and NT-proBNP signifi-
cantly correlated with NYHA functional classification.
Comparison of natriuretic peptides in NYHA groups
According to NYHA classification 35.8% were in NHYA 1,
19.5% in NYHA 2, 30% in NYHA 3 and 14.7% belonged
to NYHA 4. Median BNP in these four classes were 80.8
(42.6-163.2), 200 (118.7-331), 478 (144.1 - 742.7), and
409.4 (285.8-720.3) pg/ml respectively. Post-hoc test was
applied for multiple comparisons, using Bonferroni alpha
(0.05), which revealed significant differences in log BNP
between NYHA Class I, II and III whereas differences
were non- significant between NYHA Class III and IV.
Median log NT-proBNP in NYHA classes were 535.1
(191.9- 876.), 4192 (1505.8-7105), 13831 (4640.5-31230.5)
and 22520 (9693.2-35000) pg/ml respectively. There was a
significant mean difference in ANOVA results between
log NT-proBNP levels amongst all the four classes of
NYHA classification (p-value <0.05). A progressive decline
in eGFR with a rise in NYHA class was noted (r = − 0.2,
p-value <0.05).
Renal dysfunction and natriuretic peptides
Both natriuretic peptides showed rising trend as eGFR de-
clined as depicted in Figure 1. Median BNP values in CKD
3, 4 and 5 were 106.3 (43.1 - 281.6), 266.6 (108.9 - 589.3)
and 328.9 (142.1 - 650.6) pg/ml respectively. Median NT-
proBNP values in CKD 3, 4 and 5 were 799 (227 – 5230),
5004 (905.5 - 14776.5), and 11215.5 (3532.5 – 35000) pg/
ml respectively.
Plasma BNP and NT-proBNP levels increased stepwise
as kidney function deteriorated and the levels were signifi-
cantly higher as the SHF worsened (Figure 2A and B).
Highest BNP levels were noted in CKD stage 5 along with
NYHA class 3 and highest NT-proBNP concentration was
noted in CKD stage 5 along with NYHA class 3.
A continuous relationship of both peptides was revealed
by head to head comparison of log BNP and log NT-
Table 2 Predictors of log NT-proBNP in multivariate regression analysis
Variables Predictors of log BNP Predictors of log NT-proBNP
B standardized
coefficient
Confidence
Interval
p value B standardized
coefficient
Confidence
Interval
p value
Age 0.055 −0.003 to 0.007 0.40 −0.108 −0.011 to 0.000 0.03
Creatinine −0.030 −0.054 to 0.038 0.74 −0.079 −0.085 to 0.024 0.26
Body Mass Index 0.008 −0.014 to 0.031 0.46 0.104 0.003 to 0.053 0.02
Duration of kidney disease 0.095 0.000 to 0.004 0.12 −0.029 −0.003 to 0.002 0.53
Heart Failure −0.134 −0.445 to 0.147 0.32 0.262 0.077 to 0.800 0.01
NYHA stage 0.075 −0.089 to 0.165 0.55 0.634 0.368 to 0.617 0.00
Ejection fraction 0.045 −0.008 to 0.010 0.76 0.138 −0.004 to 0.017 0.22
eGFR 0.070 −0.005 to 0.011 0.48 −0.468 −0.036 to −0.019 0.00
Log BNP/NT-proBNP 0.729 0.358 to 0.615 0.00 0.468 0.341 to 0.595 0.00
Abbreviations: BNP b-type natriuretic peptide, NT-proBNP amino terminal B-type natriuretic peptide, NYHA New York Heart Association, eGFR estimated glomerular
filtration rate, ARB angiotensin receptor blocker.
p-value <0.05 statistically significant.
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Figure 1 Scatter plot of log transformed plasma B-type
natriuretic peptide (BNP) and amino terminal B-type natriuretic
peptide (NT-proBNP) in relation to estimated glomerular filtration
rate (eGFR). Lines of best linear fit are drawn.
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proBNP in the total group of patients. Log transformed
BNP levels correlated with log transformed NT-proBNP
levels (r = 0.43, p-value <0.05). The association of BNP
with NT-proBNP was higher in those suffering from kid-
ney dysfunction alone without SHF (r = 0.7, p-value <0.05)
compared to those suffering from kidney dysfunction and
SHF (r = 0.55, p-value <0.05). Non-significant correlation
with each other was shown by both peptides in the group
with SHF along with CKD 5.
Concentration of BNP and NT-proBNP were not
interchangeable. The mean BNP levels showed a 1.5 fold
increase from CKD stage 3 to CKD stage 5 in those
without SHF. In patients with SHF, a 2.5 fold increase
was observed in BNP levels as the CKD stage progressed
from CKD stage 3 to 5. A marked rise in mean NT-
proBNP levels was noted in non-heart failure group and
levels were three fold higher in CKD stage 5 compared
to CKD stage 3. Similarly mean NT-proBNP levels were
four times higher in CKD stage 5 compared to CKD
stage 3 in patients with SHF.
Receiver operator curve (ROC) analysis and recommended
cutoffs
The assays for BNP and NT-proBNP remained sensitive
and specific among patients with impaired kidney func-
tion as indicated by the AUC (Figure 3). On ROC
analysis the AUC for BNP and NT-proBNP was 0.7 (95%
CI 0.63 – 0.78, p-value <0.05) and 0.86 (95% CI 0.81 –
0.91, p-value <0.05) respectively (Figure 4). Figure 4A, B
and C shows the ROC analysis of BNP and NT-proBNP
according to CKD stratification. The optimal cutoffs of
BNP and NT-proBNP for diagnosing SHF for the entire
study group and also according to CKD staging are
shown in Tables 3 and 4.
Discussion
Multiple trials have reported that impaired kidney func-
tion augments the levels of these natriuretic peptides but
the optimal cutoffs are not well known with various pa-
tients’ population. This is the first study from this part
of the world and adds to the clinical utility of these car-
diac markers in specific renal population. The study
population represents typical outpatients with known
kidney dysfunction, a highly relevant population group
to explore the utility of BNP and NT-proBNP as heart
failure markers. Current study addressed the utility of
BNP and NT-proBNP as heart failure markers in kidney
patients. The results of this study are in concordance
with previous studies and revealed an inverse relation-
ship between kidney function and BNP (r = − 0.3) and
NT-proBNP (r = − 0.5) [12,28-31]. A head to head com-
parison between BNP and NT-proBNP revealed that
NT-proBNP was much higher as compared to BNP in
the SHF group and both values were not interchange-
able. Using ROC analysis, the AUC for NT-proBNP was
better than BNP in the entire study population, as well
as in subgroups of CKD stages.
In this study group, plasma NT-proBNP levels were
more affected by declining eGFR as compared to plasma
BNP levels plus the optimal cut off for plasma NT-
proBNP in the diagnosis of SHF was markedly influenced
by the severity of kidney dysfunction. A great deal of
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Figure 2 Impact of chronic kidney disease and New York Heart
Association Classification on natriuretic peptides. A. Log BNP
according to CKD stages and NYHA classification. B. Log NT-proBNP
according to CKD stages and NYHA classification.
Figure 3 Entire study group ROC curve of BNP and NT-proBNP
for heart failure. The area under the curve for BNP and NT-proBNP
was 0.70 and 0.86 respectively.
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Figure 4 Receiver-operating characteristic (ROC) curves of BNP and NT-proBNP according to chronic kidney disease (CKD) staging. (A) For CKD
stage 3 the area under the curve (AUC) for BNP and NT-proBNP was 0.66 and 0.88 respectively. (B) For CKD stage 4 the area under the curve (AUC) for BNP
and NT-proBNP was 0.74 and 0.85 respectively. (C) For CKD stage 5 the area under the curve (AUC) for BNP and NT-proBNP was 0.77 and 1.00 respectively.
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controversy exists regarding the cut-off values of BNP and
NT-proBNP levels in diagnosing SHF in patients with im-
paired kidney function. Generally the BNP and NT-
proBNP values 100 pg/ml and 125 pg/ml are considered
abnormal and suggestive of heart failure as per manufac-
turers’ product inserts. The strength of these markers is
their capability to rule out the diagnosis of acute heart fail-
ure. In general, heart failure is unlikely at BNP values
<100 pg/ml and is very likely at BNP values >500 pg/ml
and, similarly, unlikely at NT-proBNP values < 300 pg/ml
and very likely at NT-proBNP values >450 pg/ml [32-34].
McCullough et al. previously reported an analysis from
Breathing Not Properly Multinational Study in which
BNP levels were found to be related to kidney function in
patients with and without heart failure [35]. McCullough
et al. reported that it would be appropriate to apply diag-
nostic value of approximately 200 pg/ml for BNP in those
with eGFR <60 ml/min/1.73 m2. Jae Wong Yang et al.
stated that heart failure could be diagnosed in patients
with kidney dysfunction using BNP cut-off 858.5 pg/ml
with 77% sensitivity and 72% specificity [36]. Anwaruddin
et al. (PRIDE Study) noted that heart failure could be
diagnosed with 89% sensitivity and 72% specificity using
NT-proBNP cut-off of 1200 pg/ml in patient with eGFR
< 60 ml/min. It was reported that AUC for NT-proBNP in
those with GFR > 60 ml/min was 0.95 \for detecting heart
failure however, among those with GFR < 60 ml/min the
NT-proBNP assay remained sensitive and specific with
AUC of 0.88 [30]. AUC to detect heart failure tended to
be greater for NT-proBNP than that for BNP in our study
population.
Kidney dysfunction represents a variable that compli-
cates the interpretation of BNP and NT-proBNP. As
reported previously [29,30,37,38], findings of this study
propose that higher BNP and NT-proBNP cut-off points
would be needed to diagnose SHF in patients with
impaired kidney function. We propose BNP and NT-
proBNP cutoff levels of 300 pg/ml and 4502 pg/ml re-
spectively; for diagnosing SHF in patients with eGFR
<60 ml/min. Luchner et al. demonstrated lower cut-offs;
125 pg/ml for BNP and 350 pg/ml for NT-proBNP in
post-myocardial patients with renal dysfunction. The
assay used for NT-proBNP by them was similar to
the one used in current study (Roche diagnostics) but
the mean eGFR in the impaired kidney function group
was 71 ± 12 ml/min and mostly included patients with
mild renal dysfunction [31].
Our results show that NT-proBNP was more
dependent on kidney function than BNP and but using
a higher NT-proBNP cut-off had a better diagnostic ac-
curacy than BNP. Given the high prevalence of left ven-
tricular hypertrophy and left ventricular systolic
dysfunction in patients with CKD, exclusion of heart
failure becomes important in this population. In the
present study half of the patients had SHF along with
impaired kidney and has significant implications for use
of natriuretic peptide assay. Both plasma BNP and NT-
proBNP levels correlated with NYHA symptom severity
in patients with impaired kidney function. It has been
consistently found in a large number of studies that
BNP and NT-proBNP are elevated in patients with heart
failure, and values were found to be related to disease
severity as assessed by NYHA functional class [39,40].
Strong association was found between NT-proBNP
Table 3 Potential BNP and NT-proBNP cut off levels for the assessment of systolic heart failure for all CKD subjects
Natriuretic
peptide
Group Optimal
cut
point
(pg/ml)
Sensitivity Specificity Positive
likelihood
ratio
Negative
likelihood
ratio
% %
BNP Overall 217 64.2 70 1.04 0.96
BNP Overall 254 61 75 1.14 0.90
BNP Overall 300 55 82.1 3.05 0.55
NT-proBNP Overall 799 91.6 52.6 1.99 0.16
NT-proBNP Overall 1536 84.2 71.6 4.13 0.30
NT-proBNP Overall 4502 73.7 82.1 4.17 0.30
Abbreviations: BNP B-type natriuretic peptide, NT-proBNP amino terminal B-type natriuretic peptide, AUC area under the curve, CKD chronic kidney disease.
Table 4 Potential BNP and NT-proBNP cut off levels for
the assessment of systolic heart failure according CKD
staging
Natriuretic
peptide
Group Optimal cut
point (pg/ml)
Sensitivity Specificity
% %
BNP Stage 3 CKD 146 60 65.9
BNP Stage 4 CKD 309.4 60 78.4
BNP Stage 5 CKD 491 60 88.2
NT-proBNP Stage 3 CKD 1505.8 72.2 92.7
NT-proBNP Stage 4 CKD 7767.5 70 91.9
NT-proBNP Stage 5 CKD 11215.2 94.7 100
Abbreviations: BNP B-type natriuretic peptide, NT-proBNP amino terminal
B-type natriuretic peptide, AUC area under the curve, CKD chronic
kidney disease.
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levels and left ventricular hypertrophy and dysfunction
in a recently reported large CKD cohort without heart
failure. In the same study NT-proBNP improved the
ability of clinical models to predict systolic dysfunction
in CKD patients [41].
Overtly symptomatic patients (n = 28) in our study clas-
sified under NYHA class four had extremely high BNP
and NT-proBNP levels (median 409.4 and 22520 pg/ml
respectively). The biological activity of BNP includes diur-
esis, natriuresis, and inhibition of renin-angiotensin sys-
tem, endothelin secretion, and systemic and renal
sympathetic activity. Paradoxically, in congestive heart fail-
ure high BNP levels measured by conventional assays are
associated with an absence of effect of this hormone [42].
The phenomena of ‘endocrine paradox’ of the heart are
characterized by extremely high circulating levels of natri-
uretic peptides in heart failure patients, showing signs of
fluid retention and vasoconstriction [43,44]. Some recent
findings suggest that the commercially available immuno-
assay methods tend to progressively overestimate the real
biological activity of the natriuretic peptides in patients
with heart failure [45].
The studied population already suffered from impaired
kidney function; hence duration of the disease may be a
confounder in the current study. Ideally occult myocar-
dial ischemia which raises BNP and NT-proBNP levels
should have been excluded. Use of Cockcroft Gault
equation to estimate GFR is controversial in Asians pop-
ulations but good agreement between Cockcroft Gault
and creatinine clearance has been observed in our setup
[33]. Patients with CKD suffer from both systolic and
diastolic heart failure but then in the current study pa-
tients with heart failure with preserved systolic function
were not considered. Another limitation of the study is
small sample size in subcategories of the data and fur-
ther studies are required to reliably derive cutoffs. Differ-
ences exist in analytical performances of different BNP
and MT-proBNP assays therefore it may be not right to
suggest identical cut-off or decision values for all BNP/
NT-proBNP immunoassays [46].
Conclusion
Product inserts by manufacturers of plasma BNP and
NT-proBNP only have a single cut-off used in normal
population and there is no mention of limitations of
using them in patients with compromised renal func-
tion. The fact remains that many patients with heart
failure also have renal insufficiency. Therefore, current
study becomes very important in making clinicians
aware of how to interpret the results in concomitant
renal disease and also for kit manufacturers to include
it in their product labeling. Both natriuretic peptides’
assays can be used in patients with impaired kidney
function but by using higher cutoffs stratified according
to kidney dysfunction. NT-proBNP appears to predict
SHF better than BNP. Kidney dysfunction makes the
interpretation of these natriuretic peptides compli-
cated. To improve the quality of care and subsequent
prognosis, plasma BNP and especially NT-proBNP
values should be interpreted in relation to the severity
of kidney dysfunction.
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